451 related articles for article (PubMed ID: 29352109)
41. Differential effects of B and T lymphocyte attenuator and programmed death-1 on acceptance of partially versus fully MHC-mismatched cardiac allografts.
Tao R; Wang L; Han R; Wang T; Ye Q; Honjo T; Murphy TL; Murphy KM; Hancock WW
J Immunol; 2005 Nov; 175(9):5774-82. PubMed ID: 16237069
[TBL] [Abstract][Full Text] [Related]
42. Slow down and survive: Enigmatic immunoregulation by BTLA and HVEM.
Murphy TL; Murphy KM
Annu Rev Immunol; 2010; 28():389-411. PubMed ID: 20307212
[TBL] [Abstract][Full Text] [Related]
43. Distinct Changes of BTLA and HVEM Expressions in Circulating CD4
Liu J; Li J; He M; Zhang GL; Zhao Q
J Immunol Res; 2018; 2018():4561571. PubMed ID: 30116751
[TBL] [Abstract][Full Text] [Related]
44. Targeting BTLA with the peptide inhibitor HVEM(14-39) - A new way to restore the activity of T cells in melanoma.
Wojciechowicz K; Kuncewicz K; Rutkowski J; Jassem J; Rodziewicz-Motowidło S; Wardowska A; Spodzieja M
Biomed Pharmacother; 2024 Jun; 175():116675. PubMed ID: 38733770
[TBL] [Abstract][Full Text] [Related]
45. Selective blockade of herpesvirus entry mediator-B and T lymphocyte attenuator pathway ameliorates acute graft-versus-host reaction.
del Rio ML; Jones ND; Buhler L; Norris P; Shintani Y; Ware CF; Rodriguez-Barbosa JI
J Immunol; 2012 May; 188(10):4885-96. PubMed ID: 22490863
[TBL] [Abstract][Full Text] [Related]
46. Evolutionarily divergent herpesviruses modulate T cell activation by targeting the herpesvirus entry mediator cosignaling pathway.
Cheung TC; Humphreys IR; Potter KG; Norris PS; Shumway HM; Tran BR; Patterson G; Jean-Jacques R; Yoon M; Spear PG; Murphy KM; Lurain NS; Benedict CA; Ware CF
Proc Natl Acad Sci U S A; 2005 Sep; 102(37):13218-23. PubMed ID: 16131544
[TBL] [Abstract][Full Text] [Related]
47. Increased expression of the lymphocyte early activation marker CD69 in peripheral blood correlates with histologic evidence of cardiac allograft rejection.
Schowengerdt KO; Fricker FJ; Bahjat KS; Kuntz ST
Transplantation; 2000 May; 69(10):2102-7. PubMed ID: 10852605
[TBL] [Abstract][Full Text] [Related]
48. Combined Immunotherapy With Belatacept and BTLA Overexpression Attenuates Acute Rejection Following Kidney Transplantation.
Zhang H; Wang Z; Zhang J; Gui Z; Han Z; Tao J; Chen H; Sun L; Fei S; Yang H; Tan R; Chandraker A; Gu M
Front Immunol; 2021; 12():618737. PubMed ID: 33732243
[TBL] [Abstract][Full Text] [Related]
49. Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses.
Spodzieja M; Lach S; Iwaszkiewicz J; Cesson V; Kalejta K; Olive D; Michielin O; Speiser DE; Zoete V; Derré L; Rodziewicz-Motowidło S
PLoS One; 2017; 12(6):e0179201. PubMed ID: 28594868
[TBL] [Abstract][Full Text] [Related]
50. Ligation of B and T lymphocyte attenuator prevents the genesis of experimental cerebral malaria.
Lepenies B; Pfeffer K; Hurchla MA; Murphy TL; Murphy KM; Oetzel J; Fleischer B; Jacobs T
J Immunol; 2007 Sep; 179(6):4093-100. PubMed ID: 17785848
[TBL] [Abstract][Full Text] [Related]
51. BTLA and HVEM cross talk regulates inhibition and costimulation.
Gavrieli M; Sedy J; Nelson CA; Murphy KM
Adv Immunol; 2006; 92():157-85. PubMed ID: 17145304
[TBL] [Abstract][Full Text] [Related]
52. Structural Basis of CD160:HVEM Recognition.
Liu W; Garrett SC; Fedorov EV; Ramagopal UA; Garforth SJ; Bonanno JB; Almo SC
Structure; 2019 Aug; 27(8):1286-1295.e4. PubMed ID: 31230945
[TBL] [Abstract][Full Text] [Related]
53. Pathogenic Function of Herpesvirus Entry Mediator in Experimental Autoimmune Uveitis by Induction of Th1- and Th17-Type T Cell Responses.
Sakoda Y; Nagai T; Murata S; Mizuno Y; Kurosawa H; Shoda H; Morishige N; Yanai R; Sonoda KH; Tamada K
J Immunol; 2016 Apr; 196(7):2947-54. PubMed ID: 26912321
[TBL] [Abstract][Full Text] [Related]
54. Dichotomous regulation of GVHD through bidirectional functions of the BTLA-HVEM pathway.
Sakoda Y; Park JJ; Zhao Y; Kuramasu A; Geng D; Liu Y; Davila E; Tamada K
Blood; 2011 Feb; 117(8):2506-14. PubMed ID: 21220749
[TBL] [Abstract][Full Text] [Related]
55. The intrahepatic expression and distribution of BTLA and its ligand HVEM in patients with HBV-related acute-on-chronic liver failure.
Xu H; Cao D; Guo G; Ruan Z; Wu Y; Chen Y
Diagn Pathol; 2012 Oct; 7():142. PubMed ID: 23067542
[TBL] [Abstract][Full Text] [Related]
56. HVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation.
del Rio ML; Lucas CL; Buhler L; Rayat G; Rodriguez-Barbosa JI
J Leukoc Biol; 2010 Feb; 87(2):223-35. PubMed ID: 20007250
[TBL] [Abstract][Full Text] [Related]
57. High BTLA Expression Likely Contributes to Contraction of the Regulatory T Cell Subset in Lupus Disease.
Aubergeon L; Sawaf M; Felten R; Gottenberg JE; Dumortier H; Monneaux F
Front Immunol; 2021; 12():767099. PubMed ID: 34899718
[TBL] [Abstract][Full Text] [Related]
58. Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors.
Demerlé C; Gorvel L; Mello M; Pastor S; Degos C; Zarubica A; Angelis F; Fiore F; Nunes JA; Malissen B; Greillier L; Guittard G; Luche H; Barlesi F; Olive D
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37230538
[TBL] [Abstract][Full Text] [Related]
59. Role of BTLA/HVEM network in development of gastric cancer.
Azarafza M; Tehrani M; Valadan R; Maleki I; Mohammad Mehdi Ghaffari-Hamedani S; Ghanadan A; Alizadeh-Navaei R; Ajami A
Hum Immunol; 2022; 83(8-9):637-644. PubMed ID: 35914980
[TBL] [Abstract][Full Text] [Related]
60. An investigation to assess the potential of CD25highCD4+ T cells to regulate responses to donor alloantigens in clinically stable renal transplant recipients.
Akl A; Jones ND; Rogers N; Bakr MA; Mostafa A; El Shehawy el M; Ghoneim MA; Wood KJ
Transpl Int; 2008 Jan; 21(1):65-73. PubMed ID: 17887959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
